Compare RNW & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | VRDN |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United Kingdom | United States |
| Employees | 4336 | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | N/A | 2014 |
| Metric | RNW | VRDN |
|---|---|---|
| Price | $6.18 | $23.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $7.00 | ★ $35.46 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 06-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | $11.50 | $279.00 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.39 | $13.18 |
| 52 Week High | $8.24 | $34.29 |
| Indicator | RNW | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 72.21 |
| Support Level | $5.95 | $22.14 |
| Resistance Level | $6.33 | $34.18 |
| Average True Range (ATR) | 0.18 | 0.95 |
| MACD | 0.00 | 0.22 |
| Stochastic Oscillator | 67.86 | 99.77 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.